Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Dual-pathway Inhibition versus Aspirin Monotherapy
Author(s): Dirk Sibbing , Michael J Blaha , Rajinder Chawla , et al Added: 1 year ago

Anticoagulation

Prevention & Chronic Conditions
Immune Cell Traits and Aortic Dissection: A Mendelian Randomisation Study
Author(s): Tian-le Li , Mao-long Fu , Li-hong Wang , et al Added: 9 months ago

Electrophysiology & Arrhythmia

Inherited and Congenital Cardiac Conditions
Antiplatelet Treatment with Dual Pathway Inhibition
Author(s): Tobias Geisler Added: 1 year ago

Anticoagulation

Prevention & Chronic Conditions
Semaglutide Modulates Key Pathways to Resolve MASH, Proteomic Analysis Reveals
Added: 5 months ago Source:  Radcliffe CVRM
A new study has explored the underlying mechanisms by which semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), improves outcomes in patients with metabolic dysfunction-associated steatohepatitis (MASH).¹ The research, which combined analysis of a phase 2 clinical trial with preclinical models, identified a unique proteomic signature associated with treatment and suggests that… View more

Cardiovascular Renal Metabolic
AHA 25: MAPLE-HCM Responder Analysis
Author(s): Andrew Wang Added: 2 months ago
AHA Scientific Sessions 2025 – MAPLE-HCM responder analysis shows aficamten monotherapy led to greater treatment effect when compared to metoprolol monotherapy.Dr Andrew Wang (Duke University Medical Center, Durham, NC, US) presents a responder analysis from the MAPLE-HCM trial (NCT05767346), examining clinical responses to aficamten monotherapy versus metoprolol in patients with obstructive… View more

Heart Failure
Comparative Analysis of Direct Oral Anticoagulants in Atrial Fibrillation
Author(s): Ton Duy Mai , Tri Huynh Quang Ho , Sy Van Hoang , et al Added: 8 months ago

Anticoagulation

Electrophysiology & Arrhythmia
Meta-analysis and Meta-regression Applicability
Author(s): Alberto Cordero , Carlos G Santos-Gallego , Armando Oterino , et al Added: 3 months ago

CV Disease in Special Populations
Advice for Young Colleagues and Career Pathways
Author(s): Julia Grapsa , Mirvat Alasnag , Barbara Casadei Added: 11 months ago
What is the reasoning behind the porosity of data when it comes to CV outcomes in women?Diversity, Inclusion and Equity in Cardiology hosts, Dr Mirvat Alasnag (King Fahad Armed Forces Hospital, Jeddah, SA) and Dr Julia Grapsa (Guy's and St Thomas' NHS Foundation Trust, London, UK) are joined by Prof Barbara Casadei (British Heart Foundation, University of Oxford, Oxford, UK) who offers her advice… View more
ESC 25: The VICTOR & VICTORIA Pooled Analysis
Author(s): Javed Butler Added: 4 months ago
ESC Congress 2025 - Vericiguat significantly reduced risks of CV mortality and HF hospitalisations, as well as all-cause mortality across both the VICTOR and VICTORIA Trial.Dr JavedButler (Baylor Scott & White Health, Dallas, US) joins us to discuss findings from a pooled analysis of the recent VICTOR and VICTORIA trials, with data from 11155 participants with heart failure with reduced ejection… View more

Heart Failure
ESC HF 25: Secondary Analysis of FINEARTS-HF
Author(s): Ankeet Bhatt Added: 8 months ago
ESC HF 25 - Secondary analysis of the FINEARTS-HF study shows finerenone treatment favourably influenced the risk of early heart failure readmission.Dr Ankeet Bhatt (Kaiser Permanante San Francisco Medical Center, San Francisco, US) discusses findings from the prespecified secondary analysis of the FINEARTS-HF trial (NCT04435626; Bayer). The placebo-controlled primary analysis investigated the… View more

Heart Failure